Compare EHang Holdings Ltd - ADR (EH) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs McKesson Corporation — how do they compare? EHang Holdings Ltd - ADR trades at $4.08 (market cap $309.45M), while McKesson Corporation trades at $933.06 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 350.5× EHang Holdings Ltd - ADR's market cap, and McKesson Corporation pays a 0.4% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and McKesson Corporation for 74 Days on average.
| EH | MCK | |
|---|---|---|
Market Cap | $309.45M | $108.46B |
Volume | 765,799 | 712,607 |
Sector | Industrials | Health |
52-Week High | $18.94 | $995.69 |
52-Week Low | $4.03 | $725.17 |
Typical Hold Time | 46 Days | 74 Days |
Enterprise Value | $261.14M | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $4.14, up 0.98% on the day, amid a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $275.98 million on $417.98 million revenue in 2025, with negative profit margins and ROE. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims, creating a volatile backdrop.
The outlook remains challenging due to persistent losses and regulatory scrutiny, though the company's cash position of $1.12 billion provides some buffer. Investment opportunities hinge on successful commercialization of eVTOL technology, while risks include execution missteps, intense competition, and ongoing legal probes. The stock is suitable only for high-risk investors betting on long-term AAM adoption.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
